Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the ESMO World Congress on Gastrointestinal Cancer 2022
  • CME

June 29 – July 2, 2022; Barcelona, Spain
Review expert perspectives on key data on gastrointestinal cancers presented at the ESMO World Congress on Gastrointestinal Cancer 2022.
Joleen Hubbard, MD
Rachna Shroff, MD, MS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 4, 2022 Expiration: October 3, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with gastrointestinal cancer
  • Identify subpopulations of patients with gastrointestinal cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate new data on novel agents and therapeutic approaches for patients with gastrointestinal cancer
  • Appraise how new trial findings might affect gastrointestinal cancer clinical practice in the future


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Seagen Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Joleen Hubbard, MD

Associate Professor
Gastrointestinal Oncologist
Medical Oncology
Mayo Clinic
Rochester, Minnesota

Joleen Hubbard, MD: researcher: Bayer, Boston Biomedical, Effector, Hutchingson, Incyte, MediPharma, Merck, Senhwa, Taiho, Treos Bio, TriOncology, Trovagene.
Rachna Shroff, MD, MS

Assistant Professor of Medicine
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Rachna T. Shroff, MD, MS: researcher: Bayer, Bristol-Myers Squibb, Exelixis, IMV, Loxo, Merck, Novocure, Nucana, Pieris, QED Therapeutics, Rafeal, Seagen, Taiho; consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Cami, Clovis, Genentech, Incyte, QED, Servier, Zymeworks.


Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC
Jacqueline L. Olin, MS, PharmD, BCPS, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Brian Purves, PharmD, MBA
Brian Purves, PharmD, MBA, has no relevant financial relationships to disclose.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with gastrointestinal cancer.


The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with gastrointestinal cancer.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 04, 2022, through October 03, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: February 2, 2023

Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module

Stacey Stein, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 1, 2023 Expired: January 31, 2024

Phase II trial evaluating pemigatinib for previously treated mCRC with FGF/FGFR alterations, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Updated data from the CheckMate 649 study of nivolumab + chemotherapy for advanced gastric/GEJ cancer and esophageal adenocarcinoma, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)

Released: January 30, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings